USANA Health Sciences Stock Forecast, Price & News

USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

Is USANA Health Sciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences or view top-rated stocks.

How has USANA Health Sciences' stock been impacted by COVID-19?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, USNA shares have increased by 41.1% and is now trading at $98.58.
View which stocks have been most impacted by COVID-19.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for USANA Health Sciences.

How can I listen to USANA Health Sciences' earnings call?

USANA Health Sciences will be holding an earnings conference call on Wednesday, February 9th at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday, October, 26th. The company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.30 by $0.06. The business earned $274.35 million during the quarter, compared to analysts' expectations of $268.70 million. USANA Health Sciences had a net margin of 11.05% and a trailing twelve-month return on equity of 32.68%. During the same period in the previous year, the firm earned $1.44 earnings per share.
View USANA Health Sciences' earnings history.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its board has authorized a share buyback program on Tuesday, February 9th 2021, which authorizes the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 8.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2021 earnings guidance on Tuesday, November, 2nd. The company provided EPS guidance of $5.800-$6.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.930. The company issued revenue guidance of $1.18 billion-$1.20 billion, compared to the consensus revenue estimate of $1.19 billion.

What price target have analysts set for USNA?

2 brokerages have issued twelve-month target prices for USANA Health Sciences' shares. Their forecasts range from $122.00 to $126.00. On average, they anticipate USANA Health Sciences' share price to reach $124.00 in the next year. This suggests a possible upside of 25.8% from the stock's current price.
View analysts' price targets for USANA Health Sciences or view top-rated stocks among Wall Street analysts.

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:

• Kevin G. Guest, Chairman & Chief Executive Officer
• Jim Brown, President (LinkedIn Profile)
• Walter Noot, Chief Operating Officer (LinkedIn Profile)
• G. Douglas Hekking, Chief Financial Officer
• Robert Andrew Sinnott, Chief Scientific Officer

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of USANA Health Sciences' key competitors?

Some companies that are related to USANA Health Sciences include Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), Nu Skin Enterprises (NUS), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of USNA's competitors.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.40%), Exchange Traded Concepts LLC (0.10%), State of Alaska Department of Revenue (0.04%), Louisiana State Employees Retirement System (0.03%), Diversified Trust Co (0.02%) and First Hawaiian Bank (0.02%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences.

Which institutional investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, State of Alaska Department of Revenue, Diversified Trust Co, and Louisiana State Employees Retirement System. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences or view top insider-selling stocks.

Which institutional investors are buying USANA Health Sciences stock?

USNA stock was purchased by a variety of institutional investors in the last quarter, including First Hawaiian Bank, and Exchange Traded Concepts LLC.
View insider buying and selling activity for USANA Health Sciences or or view top insider-buying stocks.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $98.58.

How much money does USANA Health Sciences make?

USANA Health Sciences has a market capitalization of $1.92 billion and generates $1.13 billion in revenue each year. The company earns $124.66 million in net income (profit) each year or $6.55 on an earnings per share basis.

How many employees does USANA Health Sciences have?

USANA Health Sciences employs 1,943 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

Where are USANA Health Sciences' headquarters?

USANA Health Sciences is headquartered at 3838 West Parkway Blvd, Salt Lake City UT, 84120.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at (801) 954-7100, via email at [email protected], or via fax at 801-954-7300.